ID   RPK-1
AC   CVCL_0B31
SY   RPK1
DR   BTO; BTO:0005470
DR   cancercelllines; CVCL_0B31
DR   Cell_Model_Passport; SIDM01633
DR   GEO; GSM862565
DR   GEO; GSM862567
DR   Wikidata; Q54951154
RX   PubMed=22490663;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=22490663).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (PubMed=22490663).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4717 ! PK-1
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122;
RA   Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M.,
RA   Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S.,
RA   Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M.,
RA   Ishida M., Motoi F., Egawa S., Unno M., Horii A.;
RT   "DCK is frequently inactivated in acquired gemcitabine-resistant human
RT   cancer cells.";
RL   Biochem. Biophys. Res. Commun. 421:98-104(2012).
//